Diadexus (VXGN) 10-Q 13 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 11, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	DDXS
Entity Registrant Name	diaDexus, Inc.
Entity Central Index Key	1,036,968
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		3,838,376

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 12,092	$ 14,946
Accounts receivable, net of reserve of $910 and $6 at June 30, 2015 and December 31, 2014, respectively	2,270	4,101
Inventory, net	274	578
Prepaid expenses and other current assets	376	500
Total current assets	15,012	20,125
Restricted cash	1,400	1,400
Property and equipment, net	441	637
Other long-term assets	95	131
Total assets	16,948	22,293
Current liabilities:
Accounts payable	595	1,023
Notes payable, current portion	3,298	957
Deferred revenues, current portion		120
Deferred rent, current portion	168	128
Unfavorable lease obligations	887	820
Accrued and other current liabilities	2,153	3,074
Total current liabilities	7,101	6,122
Non-current portion of notes payable	11,824	13,791
Non-current portion of deferred rent	104	208
Non-current portion of unfavorable lease obligation	491	957
Other long term liabilities	387	369
Total liabilities	$ 19,907	$ 21,447
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred Stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding
Common stock, $0.01 par value; 50,000,000 shares authorized; 3,835,636 and 3,783,195 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 38	$ 38
Additional paid-in capital	209,684	209,171
Accumulated deficit	(212,681)	(208,363)
Total stockholders' (deficit) equity	(2,959)	846
Total liabilities and stockholders' (deficit) equity	$ 16,948	$ 22,293

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Accounts receivable, reserve	$ 910	$ 6
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	20,000,000	20,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	3,835,636	3,783,195
Common stock, shares outstanding	3,835,636	3,783,195

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Product sales	$ 4,451	$ 6,566	$ 9,978	$ 11,577
Service revenue	120	1,035	120	1,384
License revenue		75		150
Total revenues	4,571	7,676	10,098	13,111
Operating costs and expenses:
Product costs of revenue	1,477	1,810	3,046	3,403
Service costs of revenue		142		187
Sales and marketing	1,220	2,648	2,532	5,129
Research and development	1,684	1,247	2,574	4,288
General and administrative	2,172	2,076	4,436	4,219
Provision for doubtful accounts	904	2	904	2
Total operating costs and expenses	7,457	7,925	13,492	17,228
Loss from operations	(2,886)	(249)	(3,394)	(4,117)
Interest income, interest expense and other income (expense), net:
Interest income			1	1
Interest expense	(471)	(205)	(939)	(424)
Other income (expense), net	12	13	28	11
Loss before income tax	(3,345)	(441)	(4,304)	(4,529)
Income tax provision	(3)		(14)	(12)
Net loss	(3,348)	(441)	(4,318)	(4,541)
Net loss and Comprehensive loss	$ (3,348)	$ (441)	$ (4,318)	$ (4,541)
Basic and diluted net loss per share:	$ (0.87)	$ (0.12)	$ (1.13)	$ (1.24)
Weighted average shares used in computing basic and diluted net loss per share	3,835,636	3,662,535	3,814,004	3,657,024

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net loss	$ (4,318)	$ (4,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of property and equipment and assets held for sale		(5)
Depreciation and amortization	204	280
Stock-based compensation	457	351
Provision for doubtful accounts	904	2
Noncash other (income) expense	19	17
Noncash interest associated with notes payable	415	122
Unfavorable lease	(399)	(339)
Inventory write off and obsolescence reserve	200
Changes in operating assets and liabilities
Accounts receivable	927	(1,408)
Inventory	104	107
Prepaid expenses, other current assets and other long-term assets	118	(58)
Accounts payable	(429)	169
Accrued liabilities and other long term liabilities	(920)	478
Deferred rent	(64)	(26)
Deferred revenue	(120)	(119)
Net cash used in operating activities	(2,902)	(4,970)
Investing activities:
Purchases of property and equipment	(8)	(139)
Proceeds from sale of assets		4
Net cash provided used in investing activities	(8)	(135)
Financing activities:
Principal repayment of notes payable		(1,428)
Proceeds from issuance of common stock	56	102
Net cash provided by (used in) financing activities	56	(1,326)
Net decrease in cash and cash equivalents	(2,854)	(6,431)
Cash and cash equivalents, beginning of period	14,946	16,847
Cash and cash equivalents, end of period	$ 12,092	$ 10,416

Business Overview

Business Overview	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business Overview	1. Business Overview Formation of the Company Diadexus, Inc., a Delaware corporation, is a diagnostics company developing and commercializing products that deliver healthcare providers relevant information to assist in the management of their patients throughout the course of cardiac disease. Our capabilities include proprietary manufacturing, assay development, FDA regulatory clearances, and marketing and selling products. These capabilities have enabled our evolution from a single-product business into a multi-product company with growth potential to develop additional products from our portfolio of advanced cardiac biomarkers. Since our inception, we have incurred losses, and we have relied primarily on private placements of preferred stock and debt financing, as well as on revenue generated from the sale of products, to fund our operations. As of June 30, 2015, we had an accumulated deficit of $212.7 million, working capital of $7.9 million and stockholders’ deficit of $3.0 million. In August 2014, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) to borrow up to $15 million, the entire amount of which was borrowed at a fixed interest rate of 6.95% per annum. The Loan Agreement contains a number of customary representations and warranties and customary covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates. If the Company breaches any of these covenants or it is unable to make a required payment of principal or interest, or it experiences a material adverse change to its business, it could result in a default under the Loan Agreement and the amount of the loan balance, plus accrued and unpaid interest, and final payment, and the prepayment fee, and other obligations due the lender would be come immediately payable. We may require additional funds to uplist our Common Stock from the OTC Bulletin Board to NASDAQ and to broadly commercialize our products and develop new products. Our ability to fund our operations and to conduct the required development and commercialization activities related to any new product candidates will be significantly limited if we are unable to obtain the necessary capital. We expect to seek to raise funds through equity or debt offerings, bank facilities, or other sources of capital. Additional funding may not be available when needed or on terms acceptable to us and we may need to implement additional cost cutting actions. The consent of Oxford Finance LLC will likely be required for additional debt financings. Any additional equity financing may be dilutive to stockholders, and debt financing, if available, may involve restrictive covenants. We cannot assure you that we will be able to raise any such additional funding. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, the accompanying unaudited condensed financial statements have been prepared on a consistent basis with the December 31, 2014 audited financial statements and include all adjustments, consisting of normal recurring adjustments, that are necessary to fairly state the Company’s financial position as of June 30, 2015, results of operations for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014. Effective June 30, 2015, the Company consummated a 1-for-15 reverse split of all issued and outstanding shares of common stock and concurrently reduced the number of authorized common stock to 50,000,000 shares. All share and per share amounts have been adjusted to reflect this reverse split. All references in these notes to financial statements to the “Company,” “we,” “us” and “our” refer to Diadexus, Inc., a Delaware corporation, unless the context requires otherwise.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Except for the policy listed below, the Company’s significant accounting policies are disclosed in the Company’s annual report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2015, and have not changed as of June 30, 2015. Forward currency contracts: In March 2014, the Company entered into a License and Supply Agreement with B.R.A.H.M.S. GmbH. Under the terms of the agreement, the Company paid 750,000 Euros in April 2014 and another 500,000 Euros in March 2015. The Company paid an additional 500,000 Euros in development and regulatory milestones in June 2015 and may pay up to 1,000,000 Euros in post-launch commercialized milestones and royalties on future sales. In order to reduce its foreign exchange risk, on January 30, 2015, the Company entered into two forward contracts to purchase an aggregate of 1,000,000 Euros in two tranches: 500,000 Euros in March 2015 and an additional 500,000 Euros in September 2015. The forward contract for March 2015 offset the payment due to B.R.A.H.M.S. GmbH in March 2015. The latter contract was offset by a spot contract in June 2015 when the developmental milestone was reached. The forward contracts did not qualify as a cash flow hedge. Realized and unrealized gains and losses on the forward contracts are a component of Other income (expense) in the accompanying condensed Statements of Comprehensive Loss. At June 30, 2015, there were no forward contracts outstanding. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The amendment in this ASU provides guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provides guidance to recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 is effective for public entities for annual periods, and interim periods within those years, beginning after December 15, 2017, and early adoption is not permitted. The Company will adopt the provisions of ASU 2014-09 for the fiscal year beginning January 1, 2018, and is currently evaluating the impact of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The update sets forth a requirement for management to evaluate whether there are conditions and events that raise substantial doubt about an entity's ability to continue as a going concern, a responsibility that did not previously exist in GAAP. The amendments included in this update require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period, including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 will be effective for the Company in fiscal year 2016. The Company is currently assessing the future impact of this update to its financial statements. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. The Company is evaluating the impact of this standard. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory(“ASU 2015-11”), which permits companies to measure inventory at the lower of cost and net realizable value. ASU 2015-11 applies to all business entities and is effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the impact of this standard.

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2015
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	3. Cash and Cash Equivalents The Company maintains its cash in bank accounts, which at times may exceed federally insured limits. The Company has not experienced any losses on such accounts. The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. The following is a summary of cash and cash equivalents at June 30, 2015 and December 31, 2014 (in thousands) June 30, 2015 Unrealized Unrealized Estimated Cost Basis Gains Losses Fair Value Cash and cash equivalents: Cash $ 4,044 $ — $ — $ 4,044 Money market funds 8,048 — — 8,048 Total cash and cash equivalents $ 12,092 $ — $ — $ 12,092 December 31, 2014 Unrealized Unrealized Estimated Cost Basis Gains Losses Fair Value Cash and cash equivalents: Cash $ 10,894 $ — $ — $ 10,894 Money market funds 4,052 — — 4,052 Total cash and cash equivalents $ 14,946 $ — $ — $ 14,946 Fair Value Measurements In accordance with FASB’s Accounting Standard Codification (“ASC”) 820, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The guidance establishes three levels of the fair value hierarchy as follows: Level 1: Observable inputs, such as quoted prices in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table represents the Company’s fair value hierarchy for its financial assets (cash and cash equivalents) measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 (in thousands) Fair Value Measurements Quoted Prices Significant In Active other Significant Balance at Markets for Observable Unobservable June 30, Identical Assets Inputs Inputs 2015 Level 1 Level 2 Level 3 Assets: Cash $ 4,044 $ 4,044 $ — $ — Money market funds 8,048 8,048 — — Restricted cash 1,400 — 1,400 — $ 13,492 $ 12,092 $ 1,400 $ — Fair Value Measurements Quoted Prices Significant In Active other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2014 Level 1 Level 2 Level 3 Assets: Cash $ 10,894 $ 10,894 $ — $ — Money market funds 4,052 4,052 — — Restricted cash 1,400 — 1,400 — $ 16,346 $ 14,946 $ 1,400 $ — The fair value of the notes payable is valued based on Level 2 inputs and approximates its book value. The fair value of the notes payable is based on the present value of expected future cash flows and assumptions about current interest rates and the credit worthiness of the Company. As of June 30, 2015, the notes payable is carried at face value of $15 million less any unamortized debt discount. The carrying value of other financial instruments, including cash, accounts receivable, accounts payable and other payables, approximates fair value due to their short maturities.

Inventory, Net

Inventory, Net	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory, net	4. Inventory, net Inventory consists of the following (in thousands) June 30, December 31, 2015 2014 Finished goods $ 161 $ 234 Work in process 4 271 Raw materials 109 73 $ 274 $ 578

Total Accrued and Other Current

Total Accrued and Other Current Liabilities	6 Months Ended
	Jun. 30, 2015
Payables And Accruals [Abstract]
Total Accrued and Other Current Liabilities	5. Total Accrued and Other Current Liabilities Total accrued and other current liabilities include the following as of June 30, 2015 and December 31, 2014 (in thousands) June 30, December 31, 2015 2014 Accrued payroll and related expense 876 1,084 Accrued collaborative research obligations 184 612 Accrued restructuring charges 338 736 Accrued Board of Director fees 77 248 Accrued professional services 230 147 Other current liabilities 448 247 Total accrued and other current liabilities $ 2,153 $ 3,074 Accrued research obligations at December 31, 2014 represented approximately $0.6 million in payments payable to B.R.A.H.M.S. GmbH, for the license of three heart failure markers. This balance was settled in March 2015.

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2015
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	6. Concentration of Credit Risk Revenues from the following customers represented a significant portion of total revenue for the three and six months ended June 30, 2015 and 2014 and accounts receivable as of June 30, 2015 and December 31, 2014: Revenue Revenue Accounts Receivable Three Months Ended Six Months Ended June 30, June 30, June 30, December 2015 2014 2015 2014 2015 2014 Customer A 10 % 34 % 22 % 32 % 0 % 7 % Customer B 20 % 15 % 19 % 15 % 22 % 5 % Customer C 19 % 13 % 15 % 14 % 16 % 3 % Customer D 12 % 5 % 10 % 5 % 15 % 8 % Customer E 5 % 2 % 4 % 3 % 3 % 2 % Total 66 % 69 % 70 % 69 % 56 % 25 % On June 7, 2015, the Company’s largest customer (Customer A in the table above), Health Diagnostic Laboratory, (“HDL”) filed for Chapter 11 bankruptcy. The Company recorded a $0.9 million allowance for doubtful accounts to fully reserve against the HDL accounts receivable. The Company continues to sell to HDL on a “cash-in-advance” basis subsequent to the bankruptcy filing.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2015
Notes Payable [Abstract]
Notes Payable	7. Notes Payable As noted above, in August 2014, the Company entered into a Loan Agreement with Oxford to borrow up to $15 million, the entire amount of which was borrowed at a fixed interest rate of 6.95% per annum. The obligations under the Loan Agreement are payable in 48 monthly installments which began in October 2014, with interest only payments to be made from October 2014 to September 2015, followed by 36 months of equal principal and interest payments. If the Company’s trailing six month revenues equal or exceed $15 million at the end of the fiscal month ending July 31, 2015, the Company may continue to make interest only payments through September 2016 followed by 24 months of equal principal and interest payments. The Company paid an initial fee of $150,000 for access to this loan and will be required to pay an additional $1.5 million following the earlier of loan maturity or termination. The Company may prepay all, but not less than all, of the loan amount with 10 days advance notice to Oxford and payment of a prepayment premium. In connection with the Loan Agreement, the Company issued a warrant to Oxford to purchase 60,606 shares of the Company’s common stock. The Company granted Oxford a security interest in substantially all of the Company’s personal property to secure the Company’s payment and other obligations under the Loan Agreement. The security interest does not extend to patents, trademarks and other intellectual property rights (except for the rights to payment related to the sale, licensing or disposition of such intellectual property rights) or certain other specified property. The Loan Agreement contains a number of customary representations and warranties and customary covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates. The Company is also restricted from paying dividends or making other distributions or payments of its capital stock except for repurchases of stock pursuant to employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases do not exceed $250,000 in the aggregate per fiscal year. If the Company breaches any of these covenants or it is unable to make a required payment of principal or interest, or it experiences a material adverse change to its business, it could result in a default under the Loan and Security Agreement. As of March 31, 2015, the Company was in compliance with all the covenants. The Company recorded debt discount of $470,000 associated with the Loan Agreement and the amount will be amortized as interest expense over the term of the Loan Agreement using the effective interest method. Concurrent with the execution of the Loan Agreement, in August 2014, the Company used $8.4 million of the proceeds received from the loan to repay its existing loan with Comerica Bank. All Loan and Security Agreements previously entered with Comerica Bank were terminated upon receipt of this repayment. The Company was in compliance with all the covenants with Comerica Bank prior to the repayment. The Company accounted for the repayment to Comerica Bank as a debt extinguishment since the issuance of the new loan is with another unrelated creditor. Accordingly, the Company accelerated and expensed the unamortized debt discount of $132,000, debt issuance costs of $82,000 and balloon payment of $117,000 to interest expense in August 2014. The Company recorded $81,000 of loss from the debt extinguishment as interest expense in August 2014. This amount represented a pre-payment premium pursuant to the Amended Loan and Security Agreement entered into with Comerica Bank. As of June 30, 2015, future minimum payments for the notes payable are as follows ( in thousands ) 2015 (remainder of year) $ 1,649 2016 5,554 2017 5,554 2018 5,665 Total minimum payments 18,422 Less: Amount representing interest (3,422 ) Present value of minimum payments 15,000 Less: Unamortized debt discount (329 ) Notes payable, net 14,671 Less: Notes payable, current portion (3,298 ) Add: Long term interest payable 451 Non-current portion of notes payable $ 11,824

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	8. Basic and Diluted Net Loss per Share Basic net loss per common share is based on the weighted average number of common shares outstanding during the period. Diluted net loss per common share is based on the weighted average number of common shares and other dilutive securities outstanding during the period, provided that including these dilutive securities does not increase the net loss per share. The effect of the options and warrants was anti-dilutive for the three and six months ended June 30, 2015 and 2014. The following table shows the total outstanding securities considered anti-dilutive and therefore, excluded from the computation of diluted net loss per share (in thousands) As of June 30, 2015 2014 Options to purchase common stock 627 664 Warrants to purchase common stock 191 18 Restricted stock units — 3 Total 818 684

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	9. Stock Based Compensation Stock Option Plans The Company records stock-based compensation of stock options and awards granted to employees and directors by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizing the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line or ratable basis, as appropriate. The Company issued 37,896 shares of common stock for the six months ended June 30, 2015, upon stock option exercises. Additionally, the Company issued 14,545 shares of common stock during the six months ended June 30, 2015 upon vesting of Restricted Stock Units granted as a bonus to the Chairman of the Board of Directors for her performance as Interim Executive Chair in 2014. There were no stock option exercises during the three months ended June 30, 2015. The following table summarizes stock compensation expense related to employee stock options and employee stock-based compensation for the three and six months ended June 30, 2015 and 2014, which was incurred as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Stock-based compensation expense: General and administrative $ 106 $ 139 $ 268 $ 263 Research and development 51 (30 ) 108 13 Sales and marketing 7 31 37 63 Product costs 22 7 44 12 Total stock-based compensation expense $ 186 $ 147 $ 457 $ 351 Restricted Stock Units On February 6, 2015, the Company awarded an aggregate of 14,545 fully vested RSUs as a bonus to the Chairman of the Board for her performance as Interim Executive Chair in 2014 with a grant-date fair value equal to approximately $92,000 in the aggregate, or $6.30 per share. Each RSU entitled the recipient to receive one share of the Company’s common stock upon vesting. The fair value of the RSU is based on the Company’s closing stock price on the date of grant. As of June 30, 2015, no RSUs remained outstanding. Warrants On June 30, 2015, the Board of the Company approved the issuance of a warrant to purchase 112,667 shares of the Company’s common stock with an exercise price of $6.00 per share to Lori Rafield, Ph.D., the Company’s Chief Executive Officer. The warrant bears an exercise price above the fair market value of the common stock of the Company and was issued in order to satisfy the terms of Dr. Rafield’s employment agreement as the Chief Executive Officer in lieu of a stock option grant for the same number of shares of common stock of the Company that the Board previously approved in connection with her employment. The warrant vests ratably in equal monthly installments over 48 months and expires on June 30, 2025. The fair value of the warrant was calculated using the Black-Scholes option pricing model and the following assumptions: volatility of 74.05%, risk-free rate of 1.63%, exercise price of $6.00 and expected life of 5.02 years. The fair value of the warrant was determined to be $331,000 and is amortized over the vesting period on a straight-line basis.

Restructuring and Other Charges

Restructuring and Other Charges	6 Months Ended
	Jun. 30, 2015
Restructuring And Other Charges [Abstract]
Restructuring and Other Charges	10. Restructuring and Other Charges During the twelve months ended December 31, 2014, the Company incurred $1,238,000 in employee severance costs and $60,000 in other restructuring costs. As of December 31, 2014, the entire balance of $736,000 in restructuring accrual was classified as short-term and recorded within accrued and other current liabilities in the Balance Sheet as the Company expects to pay out the remaining accrual by December 31, 2015. The following table summarizes changes in the restructuring accrual for the three and six months ended June 30, 2015 (in thousands): Three Months Ended Six Months Ended June 30, 2015 June 30, 2015 Employee Severance Costs Other Costs Total Employee Severance Costs Other Costs Total Beginning balance $ 442 $ 34 $ 476 $ 688 $ 48 $ 736 Charges — (13 ) (13 ) — (13 ) (13 ) Payments (113 ) (12 ) (125 ) (359 ) (26 ) (385 ) Ending balance $ 329 $ 9 $ 338 $ 329 $ 9 $ 338

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Lease Commitments The Company leases an office and laboratory facility (the “349 Facility”) under a long-term, non-cancelable operating lease agreement, which expires in December 2016. In 2010, the Company recorded a lease obligation associated with the 349 Facility, which contained a lease payment that exceeded current market rates. Accordingly, the Company recognized a $4.1 million unfavorable lease obligation, included in the accompanying balance sheet. The Company amortizes the unfavorable lease obligation using the effective interest rate method. Rent expense for the Company’s facilities was $431,000 and $866,000 for the three and six months ended June 30, 2015, respectively, and $460,000 and $925,000 for the three months and six months ended June 30, 2014, respectively. The terms of the lease for the 349 Facility provides for rental payments on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period. Deferred rent of $272,000 and $336,000 at June 30, 2015 and December 31, 2014, respectively, is included in the accompanying balance sheets. As of June 30, 2015, future minimum lease payments under non-cancelable operating leases are as follows (in thousands) Operating Leases 2015 (remainder of year) 1,329 2016 2,738 Total minimum lease payments $ 4,067 Research and Development Commitments and Contingencies In March 2014, the Company entered into a License and Supply Agreement (the “Agreement”) with B.R.A.H.M.S. GmbH. Under the terms of the Agreement, the Company paid 750,000 Euros in April 2014 and paid another 500,000 Euros in March 2015. The Company paid an additional 500,000 Euros in development and regulatory milestones in June 2015 and may pay up to 1,000,000 Euros in post-launch commercialized milestones and royalties on future sales.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Forward Currency Contracts	Forward currency contracts: In March 2014, the Company entered into a License and Supply Agreement with B.R.A.H.M.S. GmbH. Under the terms of the agreement, the Company paid 750,000 Euros in April 2014 and another 500,000 Euros in March 2015. The Company paid an additional 500,000 Euros in development and regulatory milestones in June 2015 and may pay up to 1,000,000 Euros in post-launch commercialized milestones and royalties on future sales. In order to reduce its foreign exchange risk, on January 30, 2015, the Company entered into two forward contracts to purchase an aggregate of 1,000,000 Euros in two tranches: 500,000 Euros in March 2015 and an additional 500,000 Euros in September 2015. The forward contract for March 2015 offset the payment due to B.R.A.H.M.S. GmbH in March 2015. The latter contract was offset by a spot contract in June 2015 when the developmental milestone was reached. The forward contracts did not qualify as a cash flow hedge. Realized and unrealized gains and losses on the forward contracts are a component of Other income (expense) in the accompanying condensed Statements of Comprehensive Loss. At June 30, 2015, there were no forward contracts outstanding.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The amendment in this ASU provides guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provides guidance to recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 is effective for public entities for annual periods, and interim periods within those years, beginning after December 15, 2017, and early adoption is not permitted. The Company will adopt the provisions of ASU 2014-09 for the fiscal year beginning January 1, 2018, and is currently evaluating the impact of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The update sets forth a requirement for management to evaluate whether there are conditions and events that raise substantial doubt about an entity's ability to continue as a going concern, a responsibility that did not previously exist in GAAP. The amendments included in this update require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period, including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 will be effective for the Company in fiscal year 2016. The Company is currently assessing the future impact of this update to its financial statements. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. The Company is evaluating the impact of this standard. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory(“ASU 2015-11”), which permits companies to measure inventory at the lower of cost and net realizable value. ASU 2015-11 applies to all business entities and is effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the impact of this standard.
Fair Value Measurements	Fair Value Measurements In accordance with FASB’s Accounting Standard Codification (“ASC”) 820, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The guidance establishes three levels of the fair value hierarchy as follows: Level 1: Observable inputs, such as quoted prices in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Basic and Diluted Net Loss per Common Share	Basic net loss per common share is based on the weighted average number of common shares outstanding during the period. Diluted net loss per common share is based on the weighted average number of common shares and other dilutive securities outstanding during the period, provided that including these dilutive securities does not increase the net loss per share.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2015
Cash And Cash Equivalents [Abstract]
Cash, and Cash Equivalents	The following is a summary of cash and cash equivalents at June 30, 2015 and December 31, 2014 (in thousands) June 30, 2015 Unrealized Unrealized Estimated Cost Basis Gains Losses Fair Value Cash and cash equivalents: Cash $ 4,044 $ — $ — $ 4,044 Money market funds 8,048 — — 8,048 Total cash and cash equivalents $ 12,092 $ — $ — $ 12,092 December 31, 2014 Unrealized Unrealized Estimated Cost Basis Gains Losses Fair Value Cash and cash equivalents: Cash $ 10,894 $ — $ — $ 10,894 Money market funds 4,052 — — 4,052 Total cash and cash equivalents $ 14,946 $ — $ — $ 14,946
Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis	The following table represents the Company’s fair value hierarchy for its financial assets (cash and cash equivalents) measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 (in thousands) Fair Value Measurements Quoted Prices Significant In Active other Significant Balance at Markets for Observable Unobservable June 30, Identical Assets Inputs Inputs 2015 Level 1 Level 2 Level 3 Assets: Cash $ 4,044 $ 4,044 $ — $ — Money market funds 8,048 8,048 — — Restricted cash 1,400 — 1,400 — $ 13,492 $ 12,092 $ 1,400 $ — Fair Value Measurements Quoted Prices Significant In Active other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2014 Level 1 Level 2 Level 3 Assets: Cash $ 10,894 $ 10,894 $ — $ — Money market funds 4,052 4,052 — — Restricted cash 1,400 — 1,400 — $ 16,346 $ 14,946 $ 1,400 $ —

Inventory, Net (Tables)

Inventory, Net (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory, net	Inventory consists of the following (in thousands) June 30, December 31, 2015 2014 Finished goods $ 161 $ 234 Work in process 4 271 Raw materials 109 73 $ 274 $ 578

Total Accrued and Other Curre20

Total Accrued and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Payables And Accruals [Abstract]
Schedule of Total Accrued and Other Current Liabilities	Total accrued and other current liabilities include the following as of June 30, 2015 and December 31, 2014 (in thousands) June 30, December 31, 2015 2014 Accrued payroll and related expense 876 1,084 Accrued collaborative research obligations 184 612 Accrued restructuring charges 338 736 Accrued Board of Director fees 77 248 Accrued professional services 230 147 Other current liabilities 448 247 Total accrued and other current liabilities $ 2,153 $ 3,074

Concentration of Credit Risk (T

Concentration of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2015
Risks And Uncertainties [Abstract]
Revenues from Customers	Revenues from the following customers represented a significant portion of total revenue for the three and six months ended June 30, 2015 and 2014 and accounts receivable as of June 30, 2015 and December 31, 2014: Revenue Revenue Accounts Receivable Three Months Ended Six Months Ended June 30, June 30, June 30, December 2015 2014 2015 2014 2015 2014 Customer A 10 % 34 % 22 % 32 % 0 % 7 % Customer B 20 % 15 % 19 % 15 % 22 % 5 % Customer C 19 % 13 % 15 % 14 % 16 % 3 % Customer D 12 % 5 % 10 % 5 % 15 % 8 % Customer E 5 % 2 % 4 % 3 % 3 % 2 % Total 66 % 69 % 70 % 69 % 56 % 25 %

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Notes Payable [Abstract]
Future Minimum Payments for Notes Payable	As of June 30, 2015, future minimum payments for the notes payable are as follows ( in thousands ) 2015 (remainder of year) $ 1,649 2016 5,554 2017 5,554 2018 5,665 Total minimum payments 18,422 Less: Amount representing interest (3,422 ) Present value of minimum payments 15,000 Less: Unamortized debt discount (329 ) Notes payable, net 14,671 Less: Notes payable, current portion (3,298 ) Add: Long term interest payable 451 Non-current portion of notes payable $ 11,824

Basic and Diluted Loss per Shar

Basic and Diluted Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Outstanding Securities Considered Anti-Dilutive, and Therefore Excluded from Computation of Diluted Net Loss Per Share	The effect of the options and warrants was anti-dilutive for the three and six months ended June 30, 2015 and 2014. The following table shows the total outstanding securities considered anti-dilutive and therefore, excluded from the computation of diluted net loss per share (in thousands) As of June 30, 2015 2014 Options to purchase common stock 627 664 Warrants to purchase common stock 191 18 Restricted stock units — 3 Total 818 684

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Compensation Expense Related to Employee Stock Options and Employee Stock Based Compensation	The following table summarizes stock compensation expense related to employee stock options and employee stock-based compensation for the three and six months ended June 30, 2015 and 2014, which was incurred as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Stock-based compensation expense: General and administrative $ 106 $ 139 $ 268 $ 263 Research and development 51 (30 ) 108 13 Sales and marketing 7 31 37 63 Product costs 22 7 44 12 Total stock-based compensation expense $ 186 $ 147 $ 457 $ 351

Restructuring and Other Charg25

Restructuring and Other Charges (Tables)	6 Months Ended
	Jun. 30, 2015
Restructuring And Other Charges [Abstract]
Summary of Changes in Restructuring Accrual	The following table summarizes changes in the restructuring accrual for the three and six months ended June 30, 2015 (in thousands): Three Months Ended Six Months Ended June 30, 2015 June 30, 2015 Employee Severance Costs Other Costs Total Employee Severance Costs Other Costs Total Beginning balance $ 442 $ 34 $ 476 $ 688 $ 48 $ 736 Charges — (13 ) (13 ) — (13 ) (13 ) Payments (113 ) (12 ) (125 ) (359 ) (26 ) (385 ) Ending balance $ 329 $ 9 $ 338 $ 329 $ 9 $ 338

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Non-Cancelable Operating Leases	As of June 30, 2015, future minimum lease payments under non-cancelable operating leases are as follows (in thousands) Operating Leases 2015 (remainder of year) 1,329 2016 2,738 Total minimum lease payments $ 4,067

Business Overview - Additional

Business Overview - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Aug. 31, 2014USD ($)
Schedule Of Description Of Business [Line Items]
Accumulated deficit	$ (212,681)	$ (208,363)
Working capital	7,900
Stockholders' equity	(2,959)	$ 846
Notes payable, net	$ 14,671
Reverse stock split ratio	15
Reverse split description	1-for-15
Common stock, shares authorized | shares	50,000,000	50,000,000
Oxford Finance LLC loan [Member]
Schedule Of Description Of Business [Line Items]
Notes payable, net			$ 15,000
6.95% Notes Payable Fixed Interest Rate [Member] | Oxford Finance LLC loan [Member]
Schedule Of Description Of Business [Line Items]
Interest rate on loan			6.95%

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2014EUR (€)	Mar. 31, 2014EUR (€)	Jun. 30, 2015EUR (€)Integer	Sep. 30, 2015EUR (€)	Mar. 31, 2015EUR (€)	Jan. 30, 2015EUR (€)Integer
Forward Currency Contracts [Member]
Significant Accounting Policies [Line Items]
Number of forward contract purchased | Integer						2
Amount of forward contract						€ 1,000,000
Number of forward contracts outstanding | Integer			0
Forward Currency Contracts [Member] | Tranches 1 [Member]
Significant Accounting Policies [Line Items]
Amount of forward contract					€ 500,000
Scenario, Forecast [Member] | Forward Currency Contracts [Member] | Tranches 2 [Member]
Significant Accounting Policies [Line Items]
Amount of forward contract				€ 500,000
License and Supply Agreement [Member]
Significant Accounting Policies [Line Items]
Payment under license and supply agreement	€ 750,000
Upfront milestone to be settled					€ 500,000
License and Supply Agreement [Member] | Development and regulatory milestones [Member] | Potential [Member]
Significant Accounting Policies [Line Items]
Payment under license and supply agreement			€ 500,000
License and Supply Agreement [Member] | Development and regulatory milestones [Member] | Potential [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Payment under license and supply agreement			500,000
License and Supply Agreement [Member] | Post-launch commercial milestones [Member] | Potential [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Payment under license and supply agreement		€ 1,000,000	€ 1,000,000

Cash and Cash Equivalents - Cas

Cash and Cash Equivalents - Cash, and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Cost Basis	$ 12,092	$ 14,946	$ 10,416	$ 16,847
Cash and cash equivalents, Estimated Fair Value	12,092	14,946
Cash [Member]
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Cost Basis	4,044	10,894
Cash and cash equivalents, Estimated Fair Value	4,044	10,894
Money market funds [Member]
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Cost Basis	8,048	4,052
Cash and cash equivalents, Estimated Fair Value	$ 8,048	$ 4,052

Cash and Cash Equivalents - Fai

Cash and Cash Equivalents - Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis (Detail) - Fair value, measurements, recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	$ 13,492	$ 16,346
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	12,092	14,946
Significant other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	1,400	1,400
Cash [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	4,044	10,894
Cash [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	4,044	10,894
Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	8,048	4,052
Money market funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	8,048	4,052
Restricted cash [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	1,400	1,400
Restricted cash [Member] | Significant other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Measurements	$ 1,400	$ 1,400

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail) $ in Millions	Jun. 30, 2015USD ($)
Fair Value Disclosures [Abstract]
Notes payable face value	$ 15

Inventory, Net - Inventory (Det

Inventory, Net - Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 161	$ 234
Work in process	4	271
Raw materials	109	73
Total inventory	$ 274	$ 578

Total Accrued and Other Curre33

Total Accrued and Other Current Liabilities - Schedule of Total Accrued and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Accrued payroll and related expense	$ 876		$ 1,084
Accrued collaborative research obligations	184		612
Accrued restructuring charges	338	$ 476	736
Accrued Board of Director fees	77		248
Accrued professional services	230		147
Other current liabilities	448		247
Total accrued and other current liabilities	$ 2,153		$ 3,074

Total Accrued and Other Curre34

Total Accrued and Other Current Liabilities - Additional Information (Detail) $ in Millions	Dec. 31, 2014USD ($)
License and Supply Agreement [Member]
Accrued Expenses And Other Liabilities [Line Items]
Accrued research obligations	$ 0.6

Concentration of Credit Risk -

Concentration of Credit Risk - Revenues from Customers (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	66.00%	69.00%	70.00%	69.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			56.00%		25.00%
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	10.00%	34.00%	22.00%	32.00%
Customer A [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			0.00%		7.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	20.00%	15.00%	19.00%	15.00%
Customer B [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			22.00%		5.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	19.00%	13.00%	15.00%	14.00%
Customer C [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			16.00%		3.00%
Customer D [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	12.00%	5.00%	10.00%	5.00%
Customer D [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			15.00%		8.00%
Customer E [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable	5.00%	2.00%	4.00%	3.00%
Customer E [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue and Accounts Receivable			3.00%		2.00%

Concentration of Credit Risk 36

Concentration of Credit Risk - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 07, 2015	Dec. 31, 2014
Concentration Risk [Line Items]
Accounts receivable, reserve	$ 910		$ 6
Health Diagnostic Laboratory [Member]
Concentration Risk [Line Items]
Accounts receivable, reserve		$ 900

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail)	1 Months Ended	6 Months Ended
	Aug. 31, 2014USD ($)shares	Jun. 30, 2015USD ($)Installment	Jun. 30, 2014USD ($)
Debt Instrument [Line Items]
Notes payable, net		$ 14,671,000
Debt discount		329,000
Amortization of debt discounts	$ 132,000	$ 415,000	$ 122,000
Oxford
Debt Instrument [Line Items]
Notes payable, net	$ 15,000,000
Interest rate on loan	6.95%
Oxford | Loan Agreement [Member]
Debt Instrument [Line Items]
Period for monthly installment		monthly
Date of debt first payable installments		Oct. 31, 2014
Initial period for payment of interest only		Oct. 31, 2014
Closing period for payment of interest only		Sep. 30, 2015
Minimum trailing six month revenues to continue making interest only payments through September 2016 followed by 24 months of equal principal and interest payments	$ 15,000,000
Description of loan and security agreement		The obligations under the Loan Agreement are payable in 48 monthly installments which began in October 2014, with interest only payments to be made from October 2014 to September 2015, followed by 36 months of equal principal and interest payments. If the Company’s trailing six month revenues equal or exceed $15 million at the end of the fiscal month ending July 31, 2015, the Company may continue to make interest only payments through September 2016 followed by 24 months of equal principal and interest payments.
Debt instrument number of installments | Installment		48
Debt instrument number of installments with interest only payments | Installment		24
Debt instrument number of equal principal and interest payments interest only payments | Installment		36
Loan processing fee	150,000
Additional fee required	$ 1,500,000
Advance notice period to the bank		10 days
Warrant issued to purchase common stock | shares	60,606
Debt instrument, restrictive covenants		The Loan Agreement contains a number of customary representations and warranties and customary covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness and transactions with affiliates. The Company is also restricted from paying dividends or making other distributions or payments of its capital stock except for repurchases of stock pursuant to employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases do not exceed $250,000 in the aggregate per fiscal year. If the Company breaches any of these covenants or it is unable to make a required payment of principal or interest, or it experiences a material adverse change to its business, it could result in a default under the Loan and Security Agreement. As of March 31, 2015, the Company was in compliance with all the covenants.
Debt instrument financial covenants	$ 250,000
Debt discount	470,000
Comerica Bank
Debt Instrument [Line Items]
Repayments of loan with Comerica Bank	8,400,000
Amortization of debt issuance costs	82,000
Balloon payments expensed on early repayment of loan	117,000
Loss from extinguishment of debt	$ (81,000)

Notes Payable - Future Minimum

Notes Payable - Future Minimum Payments for Notes Payable (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
2015 (remainder of year)	$ 1,649
2,016	5,554
2,017	5,554
2,018	5,665
Total minimum payments	18,422
Less: Amount representing interest	(3,422)
Present value of minimum payments	15,000
Less: Unamortized debt discount	(329)
Notes payable, net	14,671
Less: Notes payable, current portion	(3,298)	$ (957)
Add: Long term interest payable	451
Non-current portion of notes payable	$ 11,824	$ 13,791

Basic and Diluted Loss per Sh39

Basic and Diluted Loss per Share - Outstanding Securities Considered Anti-Dilutive, and Therefore Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	818	684
Options to purchase common stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	627	664
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	191	18
Restricted stock units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total		3

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 06, 2015	Jun. 30, 2015	Jun. 30, 2015
Chief Executive Officer [Member] | Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrant issued to purchase common stock			112,667
Exercise price of warrants		$ 6	$ 6
Warrant vesting period			48 months
Warrant expiration date			Jun. 30, 2025
Fair value of warrant amortized over the vesting period			$ 331
Chief Executive Officer [Member] | Warrants [Member] | Black Scholes Option Pricing Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of warrants		$ 6	$ 6
Volatility rate			74.05%
Risk-free interest rate			1.63%
Expected life of warrant			5 years 7 days
Restricted stock units [Member] | Interim Executive Chair [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional common stock issued for vesting			0
Restricted Stock Units awarded to the Interim Executive Chair	14,545
Restricted Stock Units, grant-date fair value	$ 92
Restricted Stock Units, grant-date fair value per share	$ 6.30
RSU entitles the recipient to receive share of the Company's common stock upon vesting			1
Stock Option Plans [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued for stock options exercises, shares		0	37,896
Stock Option Plans [Member] | Restricted stock units [Member] | Chairman of The Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional common stock issued for vesting			14,545

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Stock Compensation Expense Related to Employee Stock Options and Employee Stock Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock-based compensation expense:
Stock-based compensation	$ 186	$ 147	$ 457	$ 351
General and administrative [Member]
Stock-based compensation expense:
Stock-based compensation	106	139	268	263
Sales and marketing [Member]
Stock-based compensation expense:
Stock-based compensation	51	(30)	108	13
Research and development [Member]
Stock-based compensation expense:
Stock-based compensation	7	31	37	63
Product costs [Member]
Stock-based compensation expense:
Stock-based compensation	$ 22	$ 7	$ 44	$ 12

Restructuring and Other Charg42

Restructuring and Other Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 13	$ 13
Restructuring reserve	338	338	$ 736	$ 476
Employee Severance Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges			1,238
Restructuring reserve	329	329	688	442
Other Restructuring Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	13	13	60
Restructuring reserve	$ 9	$ 9	$ 48	$ 34

Restructuring and Other Charg43

Restructuring and Other Charges - Summary of Changes in Restructuring Accrual (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Restructuring Cost And Reserve [Line Items]
Beginning balance	$ 476	$ 736
Charges	(13)	(13)
Payments	(125)	(385)
Ending balance	338	338	$ 736
Employee Severance Costs [Member]
Restructuring Cost And Reserve [Line Items]
Beginning balance	442	688
Charges			(1,238)
Payments	(113)	(359)
Ending balance	329	329	688
Other Costs [Member]
Restructuring Cost And Reserve [Line Items]
Beginning balance	34	48
Charges	(13)	(13)	(60)
Payments	(12)	(26)
Ending balance	$ 9	$ 9	$ 48

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2014EUR (€)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014EUR (€)	Jun. 30, 2015USD ($)	Jun. 30, 2015EUR (€)	Jun. 30, 2014USD ($)	Mar. 31, 2015EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2010USD ($)
Commitments Contingencies And Litigation [Line Items]
Lease expiration date					2016-12	2016-12
Unfavorable lease obligation expense | $										$ 4,100,000
Rent expense | $		$ 431,000	$ 460,000		$ 866,000		$ 925,000
Deferred rent | $		$ 272,000			$ 272,000				$ 336,000
License and Supply Agreement [Member]
Commitments Contingencies And Litigation [Line Items]
Payment under license and supply agreement	€ 750,000
Upfront milestone to be settled								€ 500,000
License and Supply Agreement [Member] | Development and regulatory milestones [Member] | Potential [Member]
Commitments Contingencies And Litigation [Line Items]
Payment under license and supply agreement						€ 500,000
License and Supply Agreement [Member] | Development and regulatory milestones [Member] | Potential [Member] | Maximum [Member]
Commitments Contingencies And Litigation [Line Items]
Payment under license and supply agreement						500,000
License and Supply Agreement [Member] | Post-launch commercial milestones [Member] | Potential [Member] | Maximum [Member]
Commitments Contingencies And Litigation [Line Items]
Payment under license and supply agreement				€ 1,000,000		€ 1,000,000

Commitments and Contingencies45

Commitments and Contingencies - Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Jun. 30, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2015 (remainder of year)	$ 1,329
2,016	2,738
Total minimum lease payments	$ 4,067